Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04969926 · ClinicalTrials.gov registry record

Natural History Study of Parathyroid Disorders

A clinical trial of Primary Hyperparathyroidism and Pseudohypoparathyroidism, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Recruiting
Registry status
3,000
Enrollment target
1
Study location

NCT04969926 is a study of Primary Hyperparathyroidism and Pseudohypoparathyroidism that is actively recruiting participants, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 3,000 participants, above the 323-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (829% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04969926, a study of Primary Hyperparathyroidism and Pseudohypoparathyroidism, is actively recruiting participants, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

RECRUITING
Registry status
3,000 participants
Enrollment target
1
Study location

Study Summary

Background: Parathyroid disorders are very common in the general population and include disorders of parathyroid excess, deficiency, or defects in parathyroid hormone (PTH) signaling. PTH, the main secretory product of parathyroid glands is responsible for regulation of calcium-phosphate homeostasis. Objective: i) To investigate the cause of parathyroid disorders ii) To describe evolution, natural history, and longitudinal trends of parathyroid and related disorders seen in syndromic presentations like multiple endocrine neoplasia, hyperparathyroidism-jaw tumor syndrome Eligibility: People ages 6 months older who have, are at risk of having, or are related to a person with a parathyroid or related disorder. Design: Participants will be screened with a review of their medical records. Participants will be seen, tested, and treated by doctors based on their condition. Their visits may be in person or via telehealth. Participants will complete questionnaires. They will answer questions about their physical, mental, and social health. Participants may give samples such as saliva, blood, urine, or stool. Participants may give cheek cell samples. They will do this using a cheek swab or by spitting into a cup. Adult participants may give a skin biopsy. For this, a small bit of skin is removed with a punch tool. Participants may have medical photos taken. If participants have surgery during the course of their regular care either at the NIH or at a different hospital or doctor s office, researchers will ask for some of the leftover tissue. Participants will be in the study as long as they are being seen by their doctor.

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2021-11-30
Est. Completion 2031-01-22

What the Registry Record Tells You About NCT04969926

The ClinicalTrials.gov registry entry for NCT04969926 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 323-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (829% higher). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Primary Hyperparathyroidism appearing as the primary indexed condition, and to 0 interventions.

NCT04969926 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT04969926 about?

NCT04969926 is a clinical study titled "Natural History Study of Parathyroid Disorders". Background: Parathyroid disorders are very common in the general population and include disorders of parathyroid excess, deficiency, or defects in parathyroid hormone (PTH) signaling. PTH, the main secretory product of parathyroid glands is responsible for regulation of calcium-phosphate homeostasi...

What is the current status of trial NCT04969926?

This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2021-11-30. Estimated completion is 2031-01-22.

What conditions does trial NCT04969926 study?

This clinical trial studies the following conditions: Primary Hyperparathyroidism, Pseudohypoparathyroidism, Multiple Endocrine Neoplasia, Type 1, Parathyroid Cancer, Inheritable Bone Diseases.

Who is sponsoring clinical trial NCT04969926?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04969926 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Primary Hyperparathyroidism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.